
News|Articles|November 30, 2012
FDA approves cabozantinib to treat rare type of thyroid cancer
FDA has approved cabozantinib (Cometriq, Exelixis and AstraZeneca) for the treatment of progressive, metastatic medullary thyroid cancer (MTC).
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
1,700 sites closed, 77,000 fewer children received PEPFAR-supported treatment after PEPFAR disruption | IAS 2026
2
CGM prescribed by primary care lowers A1C and acute care use in diabetes patients
3
Health Begins at Home: Why Housing Has Become a Strategic Priority for Managed Care
4
Could uveitis in patients with melanoma being treated with immune checkpoint inhibitors be a good thing?
5


























